Corvus Pharmaceuticals, Inc. (CRVS)

Pharmaceutical Preparations · market cap $1.1B · as of 2026-07-20

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-03 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Corvus Pharmaceuticals (CRVS) is a 31-employee clinical-stage biotech with a market cap of ~$1.25B and a single disclosed asset: soquelitinib, currently in Phase 3 for Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS). The company carries ~$40M in cash representing roughly 11.6 months of runway, with a high-impact Phase 3 readout estimated around November 2026.

The catalyst path

2026-11-03 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Soquelitinib	Phase 3	Peripheral T-Cell Lymphoma, Not Otherwise Specified

Price & technical context

3-month

-25.5%

6-month

-21.3%

12-month

+54.0%

52-wk range

$6.50–$25.52

vs 50-day MA

-16.2%

vs 200-day MA

-19.8%

Realized vol

118.0%

Max drawdown

-70.5%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CRVS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.